Brexpiprazole is a drug used to either treat Schizophrenia or to prevent its relapse. It is also approved for use as an adjuvant in the treatment of Major Depressive Disorder (MDD), as an add-on when first line antidepressants fail to provide sufficient clinical results. Brexpiprazole has been launched under the brand name Rexulti.
Brexpiprazole was considered a major newcomer in 2015, with the potential to become the next blockbuster in mental health disorders. Drugs used in mental health have always maintained their position in top ten selling groups of drugs globally, and will continue to do so as per the IMS Institute for Healthcare Informatics report titled “Global Outlook for Medicines Through 2018”.
Brexpiprazole is classified as an atypical antipsychotic and adjunctive antidepressant, having a dopamine and serotonin receptor partial agonism. It is very similar in action to Aripiprazole (better known as Abilify), which has long maintained its position as one of the top 10 selling drugs in the US, and as one of the best-selling drugs for mental health globally. Brexpiprazole offers the benefit of improved pharmacokinetics and safety profile (lesser extrapyramidal side effects like restlessness and agitation). This is especially important, as both Schizophrenia and MDD are chronic diseases.